A-Alpha Bio leverages synthetic biology and machine learning to measure, discover, predict, and engineer protein-protein interactions. Their mission is to improve human health by unlocking the potential of protein-protein interactions. They generate high-resolution data to discover and optimize rare and effective antibodies, identify compatible protein pairs for molecular glues, and fuel machine-learning models to accelerate the discovery and optimization of high-impact drugs.

A-Alpha Bio

A-Alpha Bio is a biotechnology company using synthetic biology and machine learning to measure, discover, predict, and engineer protein-protein interactions. We pursue our mission of improving human health through an internal therapeutics pipeline and by partnering with industry-leading pharmaceutical and technology companies.

Current approaches for measuring protein-protein interactions are insufficient for many drug development applications due to low accuracy or throughput. We are a team of synthetic biologists, structural biologists, and next-generation sequencing experts who have come together to remove this industry-wide bottleneck. Our proprietary experimental platform, AlphaSeq, generates high-resolution data to discover rare and effective antibodies, identify degradable neo-substrates for molecular glues, and generate massive protein-protein interaction datasets to map the protein binding landscape. Our AlphaBind platform then leverages these data to train predictive machine learning models to further accelerate the discovery and optimization of high-impact therapeutics.

A-Alpha Bio, Inc. was founded in 2017 as a spinout from the University of Washington's Institute for Protein Design and Center for Synthetic Biology and is based in Seattle, Washington.

National Science Foundation

U.S. Department of Defense

Bill & Melinda Gates Foundation

AME Cloud Ventures

Washington Research Foundation

Sahsen Ventures

OS Fund

Madrona

Boom Capital

Perceptive Advisors

Lux Capital

Farvatn Venture

Breakout Ventures

We are excited to participate in the 2nd Annual Molecular Glue Drug Development Summit in Boston this week! During the summit, we will share our latest work on applying AlphaSeq and AlphaBind for molecular glue discovery. 

In his talk, A-Alpha Bio Co-Founder and CTO Randolph Lopez will showcase how we use our platforms to improve the efficiency of identifying latent E3 ligase-target interactions using high-throughput experiments and machine learning. 

A-Alpha Bio Senior Scientist Arpita Sen will present a poster on how our platforms enable a high-throughput approach to discover novel glueable ligase-target pairs. 

If you’re attending, catch Randolph’s talk and stop by Arpita’s poster on February 1st to learn more. 
 
#molecularglues #biotech

"I've leaned into my strengths as a multidisciplinary expert, guiding the company’s growth and expanding our platform across various therapeutic areas and applications."

A-Alpha Bio Co-Founder and CTO, Randolph Lopez, talks about his journey from growing up in Venezuela to harnessing synthetic biology and machine learning to improve human health. 

Thanks to JDI (Jones-Dilworth, Inc.) for featuring Randolph's story in The Superposition!

https://lnkd.in/gMj45saz

Now hiring for a Senior Scientist on our Immunobiology team! Come join A-Alpha Bio on our quest to improve human health!
https://lnkd.in/gNQuCP6S

A-Alpha Bio is excited to participate in the 23rd Annual PepTalk Conference in San Diego, where we will showcase our latest work in antibody design and optimization. In his talk, A-Alpha Bio Co-Founder and CTO, Randolph Lopez, will delve into the applications of our AlphaSeq and AlphaBind platforms in the discovery and optimization of rare, cross-reactive antibodies. If you're attending PepTalk, please tune in this Friday, January 19th, to learn more.

#peptalk  #biotech

We have another new open position here at A-Alpha! Check out our posting for a Scientist I on our Protein Science team.
https://lnkd.in/gaKWsSFq

We are excited to share the results of our recent collaboration with Google and Lumen Bioscience! 

With funding from the Bill & Melinda Gates Foundation, we’ve used AlphaSeq and machine learning (ML) to generate highly diverse single-domain antibodies that bind and neutralize SARS-CoV-2 variants with broad cross-reactivity. 

Through multiple iterations of AlphaSeq data generation, ML model training, and antibody design, we generated thousands of antibody variants showing enhanced binding against diverse SARS-CoV-2 strains. The most promising antibody candidates were expressed recombinantly and evaluated with biolayer interferometry and viral neutralization assays, demonstrating up to 100-fold improvement in binding and neutralization compared to the parental antibody.

The end result is twofold: (1) therapeutic variants showing potent neutralization of diverse viral variants, and (2) an ML approach that can predict binding across vast regions of sequence space and may help future-proof therapeutics against rapidly evolving pathogens. 

Check out the preprint here: https://lnkd.in/gH7GqJJm

We have yet another new open position here at A-Alpha! Check out our posting for a Senior Research Associate on our Platform R&D team.
https://lnkd.in/eCbMaS9s

A-Alpha is now hiring for an Associate Scientist on our Immunobiology team!
https://lnkd.in/gc9MSj_G

A-Alpha is newly hiring for a Senior Scientist, Computational Protein Engineering! Come join our fantastic Data Science/ML team and work with the amazingly smart, talented, and driven individuals we have here. https://lnkd.in/gpTSjyNT

A-Alpha is hiring for an entry-level Research Assistant I on our Technical Operations team! Check out our posting - this is an amazing team and they're so excited to bring another person onboard!
https://lnkd.in/grKRjWr7

COM:AALPHABIO

A-Alpha Bio

Financials Not Available